Citizens (NASDAQ:CIZN) Earns Sell Rating from Analysts at StockNews.com
by Teresa Graham · The Cerbat GemStockNews.com initiated coverage on shares of Citizens (NASDAQ:CIZN – Free Report) in a report released on Monday morning. The brokerage issued a sell rating on the bank’s stock.
Citizens Stock Performance
Shares of CIZN stock opened at $8.75 on Monday. Citizens has a 52-week low of $6.64 and a 52-week high of $10.50. The stock has a market cap of $49.35 million, a price-to-earnings ratio of 14.34 and a beta of -0.02. The firm’s 50-day moving average is $8.85 and its 200-day moving average is $8.48.
Citizens (NASDAQ:CIZN – Get Free Report) last released its quarterly earnings data on Friday, October 25th. The bank reported $0.06 earnings per share (EPS) for the quarter. Citizens had a return on equity of 7.54% and a net margin of 4.44%. The firm had revenue of $10.08 million for the quarter.
Citizens Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 16th will be issued a $0.16 dividend. The ex-dividend date of this dividend is Monday, December 16th. This represents a $0.64 annualized dividend and a dividend yield of 7.31%. Citizens’s dividend payout ratio is currently 104.92%.
About Citizens
Citizens Holding Company operates as the bank holding company for The Citizens Bank of Philadelphia that provides various commercial and personal banking products and services. It offers demand deposits; and savings and time deposit accounts. The company also provides secured and unsecured loans; mortgage loans; single and multi-family housing, farm, residential and commercial construction, and commercial real estate loans; commercial, industrial, and agricultural production loans; and consumer loans, as well as issues letters of credit.
See Also
- Five stocks we like better than Citizens
- Bank Stocks – Best Bank Stocks to Invest In
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- Earnings Per Share Calculator: How to Calculate EPS
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- 3 Fintech Stocks With Good 2021 Prospects
- 2 Generic Drug Stocks Ready to Surge in 2025